Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a $25 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c
- NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M
- NeoGenomics Inc. (NEO) Q1 Earnings Cheat Sheet
- NeoGenomics expands access to full oncology testing portfolio
- William Blair health diagnostics analyst holds analyst/industry conference call